PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Int J Geriatr Psychiatry. Author manuscript; available in PMC Aug 1, 2009.
Published in final edited form as:
PMCID: PMC2717612
NIHMSID: NIHMS115101
MEASURING PRIMARY CARE PATIENTS’ ATTITUDES ABOUT DEMENTIA SCREENING
Malaz Boustani, MD, MPH,1,2,3 Anthony J. Perkins, MS,1,2 Patrick Monahan, PhD,3 Chris Fox,4 Lea Watson, MD, MPH,6 John Hopkins, MSPH,6 Bridget Fultz, MA,1,2 Siu Hui, PhD,1,2,3 Frederick W. Unverzagt, PhD,5 Christopher M. Callahan, MD,1,2,3 and Hugh C. Hendrie, MB, ChB1,2,5
1Indiana University Center for Aging Research, Indiana University School of Medicine
2Regenstrief Institute, Inc., Indiana University School of Medicine
3Department of Medicine, Indiana University School of Medicine
4Kent Institute of Medicine and Health Sciences, University of Kent the UK
5Department of Psychiatry, Indiana University School of Medicine
6Department of Psychiatry, School of Medicine, University of North Carolina at Chapel Hill.
Corresponding Author: Malaz Boustani, MD, MPH, Regenstrief Institute, Inc., 410 West 10th Street, Suite 2000, Indianapolis, Indiana 46202-3012, Phone:317-423-5590, Fax: 317-423-5695, Email: mboustani/at/regenstrief.org
Objectives
To develop a questionnaire that will capture patients’ attitudes about dementia screening in primary care.
Methods
Cross-sectional study of 315 patients aged 65 and older attending urban and rural primary care clinics in Indianapolis and North Carolina. The Perceptions Regarding Investigational Screening for Memory in Primary Care (PRISM-PC) questionnaire was administered via face-to-face or phone interview.
Results
The PRISM-PC questionnaire consists of two separate scales: the patient’s acceptance of dementia screening scale and the patient’s perceived harms and benefits of dementia screening scale. The face validity of the PRISM-PC questionnaire was based on a systematic literature review and the opinions of 16 clinician-investigators with experience in screening for dementia. Exploratory factor analyses for the acceptance scale revealed the presence of two dimensions: knowledge about dementia risk and testing for dementia. For the benefits and harms scale, exploratory factor analyses identified four dimensions: perceived benefits of screening, stigma of screening, suffering from screening, and impact of screening on patients’ independence. The internal consistency of each of the above subscales was good with Cronbach’s alpha ranging from 0.58–0.85.
Conclusion
The PRISM-PC questionnaire captures primary care patients’ acceptance, perceived harms, and perceived benefits of dementia screening.
Keywords: Dementia, Screening, Attitudes, Harms
A global consensus of dementia epidemiologists estimated that every 7 seconds, there is a new patient diagnosed with dementia across the globe (Ferri, 2005). It is anticipated that if no scientific advances alter the incidence and progression of these dementing disorders, between 8 and 13 million people in the U.S. will be suffering from the syndrome by the year 2050 (Sloane, 2002). Dementia causes a high burden of suffering for patients and their families (Boustani, 2003).
Screening for dementia has been suggested as a method to decrease dementia burden. However, the United States Preventive Services Task Force (USPSTF) concluded that there is insufficient data to recommend for or against routine dementia screening (Boustani, 2003; USPSTF, 2003). The USPSTF found no study that evaluated the patients’ attitudes as potential patient-based barriers for dementia screening (Boustani, 2003). Most of the current available data on patients’ attitudes about dementia screening are based on scattered small surveys of genetic screening and the disclosure of dementia diagnosis (Boise, 1999; Jha, 2001; Holroyd, 1996; Holroyd, 2002; Macguire, 1996; Welkenhuysen, 1997; Neumann, 2001; Barak, 2002; Green, 1997 Husband, 2000; Roberts, 2000; Tibben, 1997; Draper, 1998). None of the previous studies evaluated the patients’ perceptions of loss of independence, such as placement in institutional settings, loss of driving privileges, or loss of insurance. As a first step in filling this gap in the literature, we developed a questionnaire, the Perceptions Regarding Investigational Screening for Memory in Primary Care questionnaire (PRISM-PC questionnaire) to capture primary care patients’ attitudes about dementia screening. This paper describes the early process of developing the PRISM-PC questionnaire and reports its psychometric properties.
The PRISM- PC questionnaire was administered to 3 different convenience samples
The first sample consisted of sampling consecutive patients age 65 years and older from seven outpatient clinics within the Indiana University Medical Group (IUMG) system. To be eligible for the study, patients had no documented history of dementia, depression, schizophrenia, or bipolar disorder and spoke English. Of the 187 eligible patients contacted, 125 (66.8%) completed the questionnaire in person with a trained interviewer. The second sample consisted of caregivers enrolled in a randomized trial of collaborative care for Alzheimer’s disease (Callahan, 2006). Patients enrolled in the study received their primary care either in the IUMG system or at the Roudeboush Veterans Affairs Medical Center in Indianapolis. Trained interviewers were able to administer the questionnaire to 81 (90%) of 90 eligible caregivers over the phone. The third sample used the North Carolina Family Practice Research Network, an established stratified random sample of 16 practices equally representing urban and rural settings in North Carolina. This sample included 109 adults ≥ 65 out of 245 eligible participants who had seen their primary care doctor at least once in the last year and met the same inclusion criteria as the Indiana samples. The questionnaire in this sample was administered over the phone by a trained interviewer. Both of the Indiana studies were approved by the Indiana University Purdue University Indianapolis Institutional Review Board and the North Carolina study was approved by the University of North Carolina at Chapel Hill Institutional Review Board. All of the participants provided consent to be enrolled in the study.
The content of the PRISM-PC questionnaire
was based on (1) health belief model, (2) review of the literature of previous attitudinal surveys of AD genetic screening and dementia diagnosis disclosure, (3) two prior studies of acceptance of dementia screening in primary care clinics and continuous care retirement communities, and (4) our clinical experience in managing patients with dementia (Boustani, 2003 (A, B); Boustani, 2006). We used the Health Belief Model as the theoretical framework for the development of the PRISM-PC questionnaire. The Health Belief Model has been used to understand a person’s reluctance to engage in preventive health behavior. The components of the Health Belief Model are based upon four main concepts: the perceptions of disease susceptibility and severity, and the perceived benefits of and barriers/costs to taking a specific health action (Becker, 1974; Becker, 1975).
The PRISM-PC items aim to capture both the patient’s acceptance of dementia screening and the patient’s perception of potential harms and benefits of such a screening. A preliminary draft of the PRISM-PC questionnaire was tested for face validity by 16 clinical researchers with expertise in survey design and dementia care. These experts were asked to evaluate the content and the language of each suggested question, decide to accept or modify the question accordingly, and suggest any additional relevant questions. Based on the experts’ feedback, we modified the questionnaire’s content and language prior to initial patient pilot testing. This version (see appendix) included 46 items. Excluding respondents’ prior experience with AD and respondents’ comments, each item was rated on a 5-point Likert scale (strongly agree, agree, don’t know, disagree, and strongly disagree). All of the respondents had the opportunity, via answering section E and a direct conversation with the study interviewers, to discuss and provide any additional perceptions related to the potential harms or benefits of dementia screening. Although we were interested in patients’ attitudes abut dementia screening, we used the term Alzheimer’s disease as an alternative to dementia because our early work showed that “Alzheimer’s disease” is a more readily understood term than dementia.
The construct validity was assessed via factorial validity
The factor structure of the questionnaire was studied by using factor analysis with the principal axis method of factor extraction. The adjusted squared multiple correlations were specified as prior communalities. Factor patterns were rotated using varimax rotation. The number of factors was determined by a combination of the screen plot and clinical judgment. Cronbach’s alpha was calculated to assess internal consistency of scale scores. For all analyses, items were recoded such that 5 was equivalent to strongly agree and 1 was equivalent to strongly disagree.
The mean age of the study participants was 72.8 (SD, 9.1); 70% of the patients were female, 44% were African-American, 39% had at least a high school education, 33% were living alone, and 40% were married. The mean administration time for PRISM-PC ranged from 20 to 26 minutes. The item language, mean score and the percentage of missing data are presented in Table 1. No new additional items were identified by the participants and approximately 95% of the participants felt comfortable answering the questions.
Table 1
Table 1
Item score, SD, and percentage of missing data
The VARIMAX-rotated factor loadings for the 8 screening acceptance items are presented in Table 2. The screen plot suggested the existence of one or two factors. Specifically, the eigenvalues of the first four factors were: 5.10, 1.03, 0.64, and 0.47, showing that the eigenvalues leveled off after two factors. Clinical judgment suggested that the two-factor solution was sensible. Specifically, we found that the 8 items on acceptance of screening loaded on two dimensions, accepting the screening to know the risk and accepting the actual testing for AD screening. We also found that two pairs of items were redundant with a high correlation of 0.81 for items 7 and 8 and correlation of 0.97 for items 12 and 13. Thus, we recommend selecting only items 7 and 13 in the final PRISM-PC questionnaire. These two factors explained 76.6% of the total variance and 90.7% of the shared variance in the eight items. Although the data suggest that scores from the acceptance scale be reported as two factors by summing the items from each subscale, it would also be appropriate to report a total score on this scale in addition to the two subscale scores given that the one-factor solution revealed loadings above .60 for all eight items.
Table 2
Table 2
Factor loadings for screening acceptance
The VARIMAX-rotated factor loadings for the 29 perceived benefits and harms items are presented in Table 3. Based on the scree plot (first four eigenvalues were 5.41, 4.42, 1.42, and 1.34) and clinical judgment, we obtained 4 major factors (see table 3). The first factor consisted of items related to benefits of dementia screening, while the second factor consisted of items related to the stigma of being diagnosed with AD. The third factor consisted of items related to insurance and loss of independence. The final factor consisted of items related to negative effects on family and emotion. One item did not load on any factor, item 16. In Table 3, the loading for each item is bolded under the factor loaded most highly. The exception was that item 39 was lumped under the Stigma factor (based on clinical judgment), despite the fact that this item loaded slightly higher (.38) on Benefits than Stigma (.37). These four factors explained 43.4% of the total variance and 78.8% of the shared variance in the eight items.
Table 3
Table 3
Factor loadings for benefits and harms of dementia screening
We report the internal consistency of all subscale scores and of the total acceptance score, using Cronbach’s alpha coefficient, in Table 4. The screening acceptance scales show good internal consistency with values of 0.77 or higher. All of the benefits and harms scales showed good internal consistency (values > 0.70) except the suffering/emotional scale.
Table 4
Table 4
Internal Consistency for the various scales of the PRISM-PC Questionnaire
We have developed, pilot tested, and validated, for the first time, a survey questionnaire which captures the attitudes of primary care patients about dementia screening. The PRISM-PC questionnaire is composed of the acceptance scale and the perceived harms and benefits scale. The acceptance scale has two underlying constructs (knowledge of dementia screening and being tested for dementia). The perceived harms and benefits scale has four constructs (benefits, stigma, suffering, and negative impact of screening on independence). The questionnaire has good face and internal validity and it is easy to administer (less than 30 minutes) via face-to-face and phone based interviews.
There are multiple barriers for dementia screening. Chief among these barriers is the patient’s refusal to proceed with a diagnostic evaluation following a positive screening test. Nearly half of the patients who screened positive for cognitive impairment refused a diagnostic evaluation (Boustani, 2005). One reason for these refusals may be the patient’s perception of the harm of dementia screening (Boustani, 2005). This hypothesis is somewhat supported by the findings from the development of our PRISM-PC questionnaire. It appears that patients have concerns about dementia screening such as losing their health insurance coverage, their driver privileges, and / or their employment positions. At the same time, the data collected via the PRISM-PC questionnaire suggests the presence of potential positive non-medical consequences of dementia screening, such as having more time for future planning for an individual’s health, financial, and housing needs and more time for an overall family discussion and planning. Both of these perceived benefits and harms are influencing the patient’s decision of accepting dementia screening. This decision in the current data is perceived favorably for the general screening method.
Our study has some limitations. It was based on a selective population with lower educational level and a higher representation of minority participants attending primary care clinics in urban Indianapolis and rural North Carolina. The sample also included patients who were caregivers and thus the generalizability of our data is limited. Our study did not conduct a confirmatory factor analysis because we did not have prior hypothesized factors to be confirmed. Instead, we reviewed the literature, used our clinical expertise, and depended on the 16 experts to identify possible items that reflected the overall benefits and harms of dementia screening. Future studies should perform confirmatory factor analyses on the factors that we have suggested here. Also, our study did not conduct test-retest reliability. We are planning to assess the day-to-day stability of the patients’ attitudes about dementia screening in a future validation study.
Capturing data via the PRISM-PC questionnaire might help clinical providers, policy makers, and health services researchers in dementia understand the patients’ perspectives related to the risks and benefits of dementia screening. Such understanding could facilitate the development of an individualized counseling program that could modify any patient-based barriers for dementia screening and lead to the successful implementation of prevention methods, in order to decrease the current and future burden of dementia.
Key Points
1)- We have developed the PRISM-PC questionnaire, which captures the attitudes of primary care patients about dementia screening.
2)- The PRISM-PC questionnaire is composed of the acceptance scale and the perceived harms and benefits scale. The acceptance scale has two underlying constructs (knowledge of dementia screening and being tested for dementia), and the perceived harms and benefits scale has four constructs (benefits, stigma, suffering, and negative impact of screening on independence).
3)- The PRISM-PC questionnaire has good face and internal validity and it is easy to administer (less than 30 minutes) via face-to-face and phone based interviews.
Supplementary Material
Acknowledgments
Supported by
Grants (P30AG024967; R01AG029884-01) from the National Institute on Aging, the Program on Aging at the University of North Carolina at Chapel Hill and the Foundation of Hope. Dr. Boustani was supported by the Paul B. Beeson K23 Career Development Award # 1-K23-AG026770-01. Mr. Hopkins was supported by the American Federation for Aging Research, Medical Student Summer Research Training in Aging Scholarship.
  • Barak Y, Aizenberg D. Suicide amongst Alzheimer's disease patients: a 10-year survey. Dement Geriatr Cogn Disord. 2002;14:101–103. [PubMed]
  • Becker MH, Maiman LA. Sociobehavioral determinants of compliance with health care and medical care recommendations. Med Care. 1975;13:10–24. [PubMed]
  • Becker MH. The health belief model and sick role behavior. Health Education Monographs. 1974;2:409–419.
  • Boise L, Camicioli R, Morgan DL, Rose JH, Congleton L. Diagnosing dementia: perspectives of primary care physicians. Gerontologist. 1999;39(4):457–464. [PubMed]
  • Boustani M, Perkins AJ, Fox C, et al. Who refuses the diagnostic assessment for dementia in Primary Care? Int J Geriatric Psychiatry. 2006;21:556–563. [PubMed]
  • Boustani M, Peterson B, Hanson L, Harris R, Lohr KN. Screening for dementia, systematic evidence review. Ann Intern Med. 2003;138:927–937. (A). [PubMed]
  • Boustani M, Watson L, Fultz B, Perkins AJ, Druckenbrod R. Acceptance of dementia screening in continuous care retirement communities. Int J Geriatr Psychiatry. 2003;18:780–786. (B). [PubMed]
  • Boustani M, Callahan CM, Unverzagt FW, et al. Implementing a screening and diagnosis program for dementia in primary care. J Gen Intern Med. 2005;20(7) 572–577l. [PMC free article] [PubMed]
  • Callahan CM, Boustani M, Unverzagt FW, et al. Effectiveness of collaborative care for older adults with Alzheimer's disease in primary care. A randomized controlled trial. JAMA. 2006;295:2148–2157. [PubMed]
  • Draper B, MacCuspie-Moore C, Brodaty H. Suicidal ideation and the 'wish to die' in dementia patients: the role of depression. Age Ageing. 1998;27:503–507. [PubMed]
  • Ferri CP, Prince M, Brayne C, et al. Alzheimer's disease International. Global prevalence of dementia: a Delphi consensus study. Lancet. 2005;366(9503):2112–2117. [PMC free article] [PubMed]
  • Frost S, Myers LB, Newman SP. Genetic screening for Alzheimer's disease: what factors predict intentions to take a test? Behav Med. 2001;27:101–109. [PubMed]
  • Green RC, Clarke VC, Thompson NJ, Woodard JL, Letz R. Early detection of Alzheimer disease: methods, markers, and misgivings. Alzheimer Dis Assoc Disord. 1997;11 Suppl 5:S1–S5. [PubMed]
  • Holroyd S, Snustad DG, Chalifoux ZL. Attitudes of older adults' on being told the diagnosis of Alzheimer's disease. J Am Geriatr Soc. 1996;44:400–403. [PubMed]
  • Holroyd S, Turnbull Q, Wolf AM. What are patients and their families told about the diagnosis of dementia? Results of a family survey. Int J Geriatr Psychiatry. 2002;17:218–221. [PubMed]
  • Husband HJ. Diagnostic disclosure in dementia: an opportunity for intervention? Int J Geriatr Psychiatry. 2000;15:544–547. [PubMed]
  • Jha A, Tabet N, Orrell M. To tell or not to tell-comparison of older patients' reaction to their diagnosis of dementia and depression. Int J Geriatr Psychiatry. 2001;16:879–885. [PubMed]
  • Maguire CP, Kirby M, Coen R, Coakley D, Lawlor BA, O'Neill D. Family members' attitudes toward telling the patient with Alzheimer's disease their diagnosis. BMJ. 1996;31:529–530. 3. [PMC free article] [PubMed]
  • Neumann PJ, Hammitt JK, Mueller C, et al. Public attitudes about genetic testing for Alzheimer's disease. Health Aff. 2001;20:252–264. [PubMed]
  • Roberts JS. Anticipating response to predictive genetic testing for Alzheimer's disease: a survey of first-degree relatives. Gerontologist. 2000;40:43–52. [PubMed]
  • Sloane PD, Zimmerman S, Suchindran C, et al. Impact of Alzheimer's disease, 2000–2050: potential implication of treatment advances. Ann Rev Public Health. 2002;23:213–331. [PubMed]
  • Tibben A, Stevens M, de Wert GM, Niermeijer MF, van Duijn CM, van Swieten JC. Preparing for presymptomatic DNA testing for early onset Alzheimer's disease/cerebral hemorrhage and hereditary Pick disease. J Med Genet. 1997;34:63–72. [PMC free article] [PubMed]
  • U.S. Preventive Services Task Force. Screening for dementia: recommendations and rationale. Ann Intern Med. 2003;138:925–926. [PubMed]
  • Welkenhuysen M, Evers-Kiebooms G, Van den Berghe H. Attitudes toward predictive testing for Alzheimer's disease in a student population. Psychiatr Genet. 1997;7:121–126. [PubMed]